FB-811

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameFB-811
Drug Alias NameRituximab biobetter (Oneness Biotech)Glycosylated rituximab (Oneness Biotech)FB811
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsAnti-CD20B cells inhibitors
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesFountain Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOneness Biotech Co Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A